When it comes to weight loss medications the FDA’s motto appears to be, “If at first you don’t get approval, try, try, again,” and it worked as an FDA advisory panel recommended the approval of Qnexa after two previous rejections (See this week’s Item #3). This might just open the door for more approvals of previously rejected medications like Contrave and Lorgess (See this week’s Item #4) as we begin to realize how bad the obesity epidemic has become and how many of these patients are developing diabetes.
We also have reports on two medications for diabetes that have been shown to reduce body fat, liraglutide (Item #8, Short-term Effects of Liraglutide on Visceral Fat Adiposity, Appetite, and Food Preference) and dapagliflozin (Item #12, Dapagliflozin Reduces Body Fat in Diabetes Patients) as we look for all medical possibilities to help our patients.
If we add these new medications to information from a new report from Temple University’s Center for Obesity Research and Education, we might just be able to help our patients help themselves to better health, without overwhelming them with too much information.
Topics: From the dLife vault. dLife takes an in-depth look at how our national food supply affects obesity and diabetes, and how people with diabetes make smart choices today. Plus, great tips for everyday eating with diabetes. Sundays on CNBC at 7 PM ET, 6 PM CT, and 4 PM PT. Catch up on dLife.com.
Join Steven Edelman, MD and Special Guest, Urban Miyares (Blinded Veteran, Entrepreneur, Motivational Speaker) for a day focused on diabetes education, health and wellness.
Please answer this week’s poll: If the FDA approves Qnexa, will you recommend it to your diabetes patients?
Check out this week’s SPECIAL FEATURE GLP-1 “Test Your Diabetes Knowledge” question!
Dave Joffe, Editor-in-chief